Americas Cancer Immunotherapy Market Research Report, By Cancer (Prostate, Colorectal, Head & Neck Cancer), Therapeutics (Monoclonal Antibodies, Immune Checkpoint Inhibitors, Vaccines), End Users (Hospitals, Academic Institutes) - Forecast till 2030
ID: MRFR/Pharma/0149-HCR | December 2022 | Region: Americas | 90 Pages
Speak to Analyst
Request a Free Sample
Americas Cancer Immunotherapy Market Scenario:
Cancer Immunotherapy is a treatment that uses a person’s immune system to fight the diseases. Some types of the cancer immunotherapies are often referred to as biologic therapies or biotherapies. The basic principle of cancer immunotherapy is to enhance a patient’s immune system to fight against cancer. This can be achieved by administrating various immune system components, such as synthesized immune proteins. In recent years, cancer immunotherapy have been extensively exploited for the treatment of the different type cancers including breast, prostate, lung cancer, and others. Increasing prevalence of cancer is one of the major drivers for the Americas cancer immunotherapy market growth during the forecast period. The most commonly prevalent cancers in the U.S. include breast cancer, lung, bronchus cancer, and others. According to the National Cancer Institute in 2016, an estimated 1,685,210 new cases of cancer were diagnosed in the U.S. and approximately 595,690 people died due to cancer within the region. Moreover, growing geriatric population and rising healthcare expenditure will boost the market growth. Additionally, growing biotech and pharmaceutical industries fuels the market growth during the projected period. However, lack of awareness, restriction in therapeutics against different cancers and high cost for the treatment may restrain the market growth from 2022-2030.
Intended Audience
- Pharmaceutical Companies
- Biotechnological Institutes
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Market Research and Consulting Service Providers
Figure 1:- Americas cancer immunotherapy market share, by region 
Sources: WHO, annual reports, press release, white paper, and company presentations
Segmentation
The Americas cancer immunotherapy market is segmented on the basis of cancer, therapeutics, and end users.
On the basis of the cancer, the Americas cancer immunotherapy market is segmented into lung cancer, prostate cancer, colorectal cancer, head & neck cancer, and others.
On the basis of the therapeutics, the Americas cancer immunotherapy market is segmented into monoclonal antibodies, immune checkpoint inhibitors, vaccines, non-specific cancer immunotherapies and adjuvants, and others. The monoclonal antibodies segment is sub segmented into naked monoclonal antibodies, conjugated monoclonal antibodies, chemolabeled antibodies, bispecific monoclonal antibodies, and others. The naked monoclonal antibodies segment, by monoclonal antibody segment, is father segmented into alemtuzumab, trastuzumab, and others. The immune checkpoint inhibitors segment is sub segmented into PD-1 inhibitors, PD-L1 inhibitors, and others. The PD-1 inhibitors segment, by immune checkpoint inhibitors, is sub segmented into pembrolizumab, nivolumab, and others. The PD-L1 inhibitors segment, by immune checkpoint inhibitors, is further segmented into atezolizumab, avelumab, and others. The non-specific cancer immunotherapies and adjuvants segment is sub segmented into cytokines, interleukins, and others.
On the basis of the end users, the Americas cancer immunotherapy market is segmented as hospitals & clinics, academic institutes, research organization, and others.
Regional Analysis
On regional basis the Americas is divided into North America and Latin America. North America is sub segmented into U.S. and Canada. North America commands for the largest market share for the Americas cancer immunotherapy market due the presence of the U.S. within the region. This large share is also attributed due to the technologically advanced healthcare market in the region which is followed by high prevalence of cancer, increasing development in cancer immunotherapy treatment and rising per capita healthcare expenditure. Moreover, growing biotechnology, healthcare and life sciences sector within the region fuels the market growth regionally. The total number of the biotechnology industries in the U.S. increased from 2,763 in 2014 and reached 2,772 in 2015. Additionally, the abundance of state of the art laboratories in the U.S. is also facilitating the cancer immunotherapy market growth.
On the other hand, Latin America is the fastest growing region due to the presence of the developing economies within the region, rising healthcare expenditure and huge patient population.
Research Methodology
Sources: WHO, annual reports, press release, white paper, and company presentation
Key players for the Americas cancer immunotherapy market
Some of the major player in the Americas cancer immunotherapy market are Amgen Inc. (U.S.), AstraZeneca (U.K), F. Hoffmann-La Roche Ltd. (Switzerland), Bayer AG (Germany), Bristol-Myers Squibb Company (U.S.), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), and others.
